Empagliflozin Reduces Risk for Nephropathy Regardless of Blood Pressure, LDL Cholesterol, HbA1c
Investigators examined renal outcomes when controlling cardiovascular risk factors, such as blood pressure, LDL-C, and HbA1c.
ADA 78th Scientific Sessions 2018
Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
Investigators analyzed real world data to examine the risk for below-knee amputations in patients with type 2 diabetes taking canagliflozin vs other medications.
Safety and Performance of Omnipod HCL for Children With Type 1 Diabetes
In children with type 1 diabetes, the Omnipod hybrid closed-loop personal model system was safe and performed well.
Chronic Kidney Disease More Common in Type 2 Diabetes Than in Type 1 Diabetes
Investigators examined the prevalence of chronic kidney disease in adults with type 1 diabetes compared with type 2 diabetes.
Implantable Continuous Glucose Monitoring Device Safe, Effective for Adolescents
The safety assessment included incidence of insertion or procedure-related removal and device-related serious adverse events through 180 after insertion.
Type 2 Diabetes Does Not Affect Pneumonia Incidence, Outcomes After Stroke
Investigators examined the incidence and outcomes of pneumonia in patients with acute ischemic stroke and type 2 diabetes.
ITCA 650 Shows Efficacy in Reducing Weight, HbA1c in Type 2 Diabetes
The ITCA 650, a small titanium osmotic mini-pump, provides a subcutaneous infusion of exenatide over 3 or 6 months.
MEDI0382 Safe, Effective for Normalizing Glucose, Weight Loss in Type 2 Diabetes
MEDI0382 reduced body weight and normalized fasting and postprandial blood glucose levels in patients with type 2 diabetes.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ADA 78th Scientific Sessions 2018
Loading... 
Loading...